PEAK PHARMACEUTICALS, INC. — Key Metrics
8 years of history · ending 2016-09-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$0
Book Value Per Share
$-0
Free Cash Flow Per Share
$-0
Cash Per Share
—
OCF Per Share
$-0
Return on Equity↑+1932.1pts
1732.1%
Return on Assets↑+89316.3pts
89128.5%
Return on Invested Capital
-861.0%
Current Ratio↓-91.8% -$0
0.01
Quick Ratio↓-91.8% -$0
0.01
Working Capital↓-260.5% -$102K
$-141K
Net Current Asset Value↓-260.5% -$102K
$-141K
Invested Capital↓-260.5% -$102K
$-141K
OCF / Net Income↓-113.7% -$1
-0.17
FCF / Net Income↓-113.7% -$1
-0.17
Accruals Ratio (Sloan)↑+104427.1pts
104492.9%
Net Debt↑+967.2% +$169K
$152K
Net Debt / EBITDA
31.17
Interest Coverage
-1062.16
Cash Coverage
-112.44
Capex Coverage
-113.26
Tangible Common Equity↓-349.7% -$137K
$-176K
TCE / Total Assets↓-12732.2pts
-13532.1%
NOPAT
$859K
Cash ROIC↑+1011.3pts
-116.4%
Capex / D&A
0.00
Reinvestment Rate
-1.7%
Stock Price (FY-end)
$6
Market Cap
$486M
P/E Ratio
417.74
Enterprise Value
$486M
EV / EBITDA
438.79
FCF Yield
-0.0%
Shareholder Yield
0.3%
R&D Yield
0.0%
Capex Yield
0.0%
Shares Variation (YoY)
3.4%
Beta (5Y)
1.37
Cost of Equity
11.3%
Cost of Debt (after tax)
-91.3%
52W High
$10
52W Low
$2
Trailing Return 1Y
-40.0%
Trailing Return 5Y
—
F-Score (Piotroski)
1.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.